During the decade of the 1970s a great deal of progress was made in elucidating how viruses cause cancer. The RNA tumor viruses were shown to harbor cellular genes, often containing mutations, that overexpressed a protein causing the cancer. Long-latency RNA tumor viruses integrated next to or near a cellular gene that was then overexpressed and contributed to the formation of the tumor. By contrast, the DNA tumor viruses encoded their own genes that had no cellular ortholog, but were essential for the initiation and maintenance of the transformed state and tumorigenesis. These viral genes encoded proteins that were expressed in tumor cells and were seen as foreign by animals harboring these tumors. The animals produced antibodies directed against these viral antigens, and for this reason, these viral proteins were called tumor antigens. Accordingly, the transforming genes contained in the SV40 tumor virus were called the large and small tumor antigens, or T and t antigens.
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In 1979, David Lane and Lionel Crawford (Lane and Crawford, 1979) and Daniel Linzer and Arnold Levine reported that the SV40 T-antigen was bound to a cellular protein that came to be called p53 and that the concentration of the p53 protein was much higher in SV40 or other transformed cells than in normal cells. In fact, temperature-sensitive mutants of T-antigen were shown to control the levels of the p53 protein in a temperature-sensitive fashion , and serum from animals bearing SV40-induced tumors contained antibodies to the p53 protein . At this same time, Lloyd Old and his colleagues showed that animals immunized with spontaneous transformed and tumorigenic cells also made antibodies to the p53 protein (DeLeo et al., 1979) . Based upon these studies, p53 came to be classified as a tumor antigen. These observations were the first clue to the mechanism of how the SV40 tumor antigen might transCorrespondence: alevine@ias.edu form cells and the next step in this investigation was to clone the gene for p53.
Several groups raced to obtain the p53 cDNA, and Moshe Oren took on this challenge in the Levine laboratory. In 1983 (Oren and Levine, 1983) , he succeeded in using immunopurified polysomes to isolate a cDNA containing a portion of the 3' untranslated region of the p53 mRNA. This fragment was used to hybrid select the P53 mRNA that was then translated in vitro and immunoprecipitated using p53 antibodies (this assay was the state of the art at the time). As Moshe Oren went back to the Weizmann Institute to start his own laboratory, his group and the Levine laboratory rushed to create or find a cDNA library that might have a fulllength clone of the p53 cDNA (not at all the state of the art at that time). The Levine laboratory approached Art Levinson at Genentech (previously a graduate student in the Levine lab), and he passed the project onto David Goeddell's lab, where one of their top cDNA cloners, Dianne Pennica, used mRNA from mouse F9 teratocarcinoma cells, isolated by Nancy Reich, to make a cDNA library that indeed had a full-length clone of p53 (Pennica et al., 1984) . At the time, nobody thought that p53 was going to be important enough to patent the cDNA clone, since SV40 transformation was not considered to be as good a model for human cancer as were oncogenes from the RNA tumor viruses. Back at the Weizmann Institute, Moshe Oren employed a mouse liver genomic library (which, in hindsight, was apparently contaminated by some clones from a transformed cell library) to find a full-length p53 gene (Bienz et al., 1984) . A comparison of the amino acid sequences predicted by the Oren genomic clone and the Pennica cDNA clone showed that they were identical except at amino acid position 135 (out of 390 amino acids), where Oren had a valine and Pennica had an alanine. Not much was made of this difference at the time.
The next step in this adventure was to determine if p53 was an oncogene that could transform cells. At the time there were two kinds of oncogenes: those that could immortalize cells in culture but had no impact upon the other properties of the transformed phenotype (myc, E1A), and those (ras, E1 B) that could fully transform permanent cell lines, but could only transform primary cells in culture when added to these cells along with myc or EIA (Land et al., 1983) . At this time, Cathy Finlay, a postdoctoral fellow who obtained her degree at the Wistar Institute working on cellular senescence, and Phil Hinds, a new graduate student, joined the Levine laboratory and began working on the transforming properties of the p53 cDNA clone we had isolated. When our cDNA clone had no transforming activity that we could observe, we were a bit surprised, but we were even more troubled by our negative result when it was shown by Moshe that his p53 genomic clone plus ras cDNA clones could transform primary rat embryo fibreblasts (Eliyahu et al., 1984) . Further, two additional labs had similar results with different p53 clones (Jenkins et al., 1984; Parada et al., 1984) . At this point, we exchanged clones with Moshe and could easily reproduce his results with his clone, and so the 135 alanine-tovaiine difference began to loom larger. The trouble was, we didn't know whether this difference was a harmless polymorphism, whether a mutation at codon 135 activated or inactivated p53's transforming ability (nor indeed which sequence was wild-type), nor even whether the presence of introns in the transforming Oren genomic clone might produce a more active splice variant. What complicated our thinking at first was that our cDNA clone came from a teratocarcinoma library (and turned out to be wild-type) and Moshe's clone came from normal mouse liver (and turned out to be a mutant).
Careful mapping and marker rescue experiments (this was before the advent of PCR) by Phil Hinds solidly established the nontransforming F9 sequence as wildtype and identified the va1135 mutation as required for transformation by the Oren genomic construct . Further, we began to appreciate the fact that most transformed cell lines in culture contain a diverse set of mutant p53 proteins and all teratocarcinoma cell lines or tumors contain a wild-type p53 protein (see Lutzker and Levine, 1996) . Our first real clue to the significance of p53 mutation in cancer was obtained when Cathy Finlay carried out transformation studies mixing the two different p53 sequences (mutant and wild-type) with EIA plus ras or myc plus ras in transformation assays. Phil Hinds then analyzed each of the transformed clones that came from the experiment, examining the p53 proteins expressed in these cells to see if they were mutant or wild-type. These experiments gave rather surprising and clear-cut answers. Our wildtype p53 cDNA clone and a genomic clone bearing the wild-type sequence blocked the ability of myc plus ras or EIA plus ras to transform cells in culture. The few transformed clones that came from these experiments expressed myc and ras or E1A and ras but had a mutant p53 protein even though we had supplied sequences encoding wild-type p53. The only transformed cells that survived this experiment had selected for a mutant p53. Further, p53 cDNA clones with several different artificial or natural mutations could cooperate with ras and transform cells (Finlay et al., 1988) or even aided EIA plus ras transformation . Thus, the P53 wild-type gene was acting like an anti-oncogene or tumor suppressor gene in these assays. When coupled with observations of a similar mutational spectrum of p53 in murine erythroleukemias (Ben David et al., 1988; Munroe et al., 1988) , these data indicated to us that the p53 mutant protein had lost tumor suppressor activity and at the same time could act upon overexpression as a dominant-negative p53 mutant to inactivate endogenous wild-type p53 in primary cells and cooperate with ras in transformation. As we were wdting the manuscript describing these studies , we appreciated the rather complete reversal of interpretations in the field that this brought about; p53 began its life as a tumor antigen. It then was classified as an oncogene that could immortalize cells and cooperate with ras. Now the wild-type gene was going to be shown to be a tumor suppressor, leading to the consequent realization that SV40 transforms cells by inactivating the p53 protein function (Finlay et al., 1989) .
After the paper about all this was submitted to Cell and in review, A. Levine went to a Cold Spdng Harbor meeting held at the Banbury Center to talk about this work. It was at that meeting that B. Vogelstein presented results demonstrating that two colon cancers from humans contained point mutations in one copy of the P53 gene and that the other allele was lost (Baker et al., 1989 ). This was a completely different path to the same conclusion that P53 was a tumor suppressor gene. But more than that, Vogelstein had shown that the p53 gene plays a role in human cancers. Research spanning the 1990s and into the 21 st century has shown this to be quite correct. P53 mutations are common in human cancers (55% of human cancers), and families have now been identified that inherit p53 mutations and develop cancers with 100% penetrance (Vogelstein et al., 2000) . The p53 protein has been shown to be a transcription factor regulating a set of genes that can mediate cell cycle arrest and apoptosis, facilitate DNA repair, or alter other cellular processes. The function of the p53 protein is to act as a checkpoint responding to a wide variety of stress signals that can originate from external or internal events. DNA damage, hypoxia, heat shock (denatured proteins), mitotic spindle damage, nucleoside triphosphate pool sizes, nitric oxide signaling, and even oncogene mutational activation in a cell, will all signal to p53 and elicit a specific response by the cell (Vogelstein et al., 2000) . The p53 protein functions as an integrator of upstream signals and then acts as a central node in a signal transduction network that responds to minimize mutations and other errors that can lead to cancers or other pathologies (Vogelstein et al., 2000) . In recent years, the regulation of the p53 protein (the central node in this network) has been a large part of the focus of this field, and this network will serve as a model for integrative biology and the evolution of cellular networks. Many additional oncogenes and tumor suppressor genes reside in this network, and it clearly plays a central role in our present day understanding of cancer in humans.
This review of the history of these experiments is a good example of how science moves ahead in a path that is often torturous, with many false leads and dead ends. It is clear, however, that progress is made because there are many scientists and many laboratodes that add key observations to a field and that these are used to build a structure upon which the next advance is made. The p53 field, which began in 1979, has benefited from hundreds of laboratories, sharing reagents and ideas, producing thousands of papers -some subset of which will make an important impact upon patients and their diseases. This all began with the conviction that the study of simple model systems, the DNA and RNA tumor viruses, could well lead to the understanding of the origins of cancer in humans. These virus groups lead us to the tumor suppressor genes and the oncogenes. While we have more to learn, we have made a good start.
